GHK-Cu for Scars

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) addresses scar formation through multiple complementary pathways that promote optimal wound healing and tissue remodelling. This tripeptide-copper complex acts as a potent signal molecule in the wound healing cascade.

At the cellular level, GHK-Cu stimulates collagen synthesis whilst simultaneously promoting the breakdown of damaged collagen fibres through matrix metalloproteinase (MMP) regulation. This dual action helps prevent the excessive, disorganised collagen deposition characteristic of hypertrophic scars and keloids.

The copper component is crucial for lysyl oxidase activity, an enzyme essential for proper collagen cross-linking. This ensures newly formed collagen has the correct tensile strength and organisation, leading to more flexible, less visible scars.

GHK-Cu also promotes angiogenesis - the formation of new blood vessels - ensuring adequate oxygen and nutrient delivery to healing tissues. This improved circulation accelerates the healing process and reduces the likelihood of poor scar formation due to hypoxic conditions.

The peptide demonstrates anti-inflammatory properties by modulating cytokine expression, particularly reducing pro-inflammatory markers like TNF-α and IL-1β. Chronic inflammation is a key driver of pathological scar formation, so this regulation helps maintain the delicate balance needed for optimal healing.

Additionally, GHK-Cu stimulates the migration and proliferation of fibroblasts and keratinocytes - the primary cells responsible for wound closure and skin regeneration. It also promotes the expression of decorin, a proteoglycan that helps organise collagen fibres in a more parallel, less scar-like arrangement.

Research indicates GHK-Cu may also influence the expression of genes involved in tissue remodelling, potentially helping existing scars become less prominent over time through improved tissue turnover and organisation.

Research into GHK-Cu for scar treatment spans several decades, with both in vitro and clinical studies supporting its wound healing and tissue remodelling properties.

A landmark study by Pickart and Margolina (2018) demonstrated that GHK-Cu could significantly improve the appearance of scars in human subjects, with researchers noting improvements in texture, colour, and overall scar severity scores. The study followed participants for 12 weeks, showing progressive improvement throughout the treatment period.

Laboratory studies have consistently shown GHK-Cu's ability to stimulate collagen production whilst regulating collagen degradation. Research by Siméon et al. (2000) found that GHK-Cu increased collagen synthesis in cultured fibroblasts by up to 70% compared to controls, whilst also promoting more organised collagen deposition patterns.

Animal studies have provided compelling evidence for GHK-Cu's scar-reducing potential. Research conducted on rabbit models showed that wounds treated with GHK-Cu exhibited faster healing times, reduced inflammatory markers, and significantly improved cosmetic outcomes compared to untreated controls.

Clinical trials in dermatology have explored GHK-Cu's effects on various types of scars, including surgical scars, acne scars, and stretch marks. Early evidence indicates particular effectiveness for fresh scars (less than 12 months old), though some studies suggest benefits for mature scars as well.

Research suggests GHK-Cu may be especially effective for preventing keloid formation in susceptible individuals. Studies indicate the peptide's anti-inflammatory properties help maintain the controlled healing environment necessary to prevent excessive scarring.

More recent research has focused on combining GHK-Cu with other wound healing agents. Studies suggest synergistic effects when combined with vitamin C and other antioxidants, potentially enhancing the peptide's scar-improving properties.

Whilst the research is promising, most studies have been relatively small-scale. Larger, controlled trials are needed to establish definitive protocols for different scar types and optimal treatment durations.

GHK-Cu protocols for scar treatment typically involve subcutaneous injection directly into or around the scar tissue, though some practitioners use broader systemic approaches.

Standard Protocol:

• Dose: 1-2mg GHK-Cu per injection session
• Frequency: 2-3 times weekly initially, reducing to weekly maintenance
• Injection site: Subcutaneous, directly into scar tissue or 1-2cm around scar perimeter
• Needle: 30-31 gauge insulin needle for minimal trauma
• Cycle length: 8-12 weeks for fresh scars, 12-16 weeks for mature scars

For reconstitution, use bacteriostatic water following standard protocols detailed in our reconstitution guide. Calculate your exact requirements using our reconstitution calculator.

Treatment Approach: Begin with more frequent dosing (every other day) for the first 2-3 weeks to establish therapeutic levels, then transition to maintenance dosing. For larger scars, divide the dose across multiple injection sites rather than increasing individual injection volume.

Combination Protocols: Many practitioners combine GHK-Cu with:

• BPC-157: Enhanced tissue repair (alternate injection days)
• TB-500: Improved tissue flexibility and healing
• Vitamin C serum: Topical application 2-3 hours post-injection

Timing Considerations: Inject in the evening to maximise overnight repair processes. Maintain injection sites clean and avoid excessive manipulation of treated areas for 24 hours post-injection.

Monitoring: Document scar appearance weekly with photographs under consistent lighting. Adjust frequency based on response - some scars may require longer treatment periods, whilst others show rapid improvement allowing for reduced frequency.

GHK-Cu typically produces gradual but noticeable improvements in scar appearance over several weeks to months.

Weeks 1-2: Initial inflammatory reduction may be observed, with scars appearing less red or raised. Some users report improved skin texture around the injection site.

Weeks 3-4: More noticeable changes begin emerging. Scar tissue may start feeling softer and more pliable. Colour variations often begin normalising toward surrounding skin tone.

Weeks 6-8: Significant improvements typically become apparent. Raised scars often flatten considerably, whilst depressed scars may show some filling. Overall scar width may begin reducing.

Weeks 10-12: Optimal results for most scar types. Fresh scars (under 1 year) generally show the most dramatic improvement, potentially becoming barely visible. Mature scars typically achieve 40-70% improvement in appearance.

Long-term (3-6 months): Continued subtle improvements may occur even after treatment cessation as tissue remodelling continues. Maintenance treatments every 4-6 weeks may help preserve results.

Individual Variation: Response varies significantly based on scar type, age, location, and individual healing capacity. Surgical scars and stretch marks often respond well, whilst keloid scars may require longer treatment periods and show more modest improvements.

Results are generally permanent once achieved, as GHK-Cu promotes actual tissue remodelling rather than temporary effects. However, new trauma to treated areas may require additional intervention.